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Blood pH is tightly maintained between 7.35 and 7.45, and acidosis
(pH <7.3) indicates poor prognosis in sepsis, wherein lactic acid
from anoxic tissues overwhelms the buffering capacity of blood.
Poor sepsis prognosis is also associated with low zinc levels and
the release of High mobility group box 1 (HMGB1) from activated
and/or necrotic cells. HMGB1 added to whole blood at physiolog-
ical pH did not bind leukocyte receptors, but lowering pH with
lactic acid to mimic sepsis conditions allowed binding, implying
the presence of natural inhibitor(s) preventing binding at normal
pH. Testing micromolar concentrations of divalent cations showed
that zinc supported the robust binding of sialylated glycoproteins
with HMGB1. Further characterizing HMGB1 as a sialic acid-binding
lectin, we found that optimal binding takes place at normal blood
pH and is markedly reduced when pH is adjusted with lactic acid to
levels found in sepsis. Glycan array studies confirmed the binding
of HMGB1 to sialylated glycan sequences typically found on
plasma glycoproteins, with binding again being dependent on zinc
and normal blood pH. Thus, HMGB1-mediated hyperactivation of
innate immunity in sepsis requires acidosis, and micromolar zinc
concentrations are protective. We suggest that the potent inflam-
matory effects of HMGB1 are kept in check via sequestration by
plasma sialoglycoproteins at physiological pH and triggered when
pH and zinc levels fall in late stages of sepsis. Current clinical trials
independently studying zinc supplementation, HMGB1 inhibition,
or pH normalization may be more successful if these approaches
are combined and perhaps supplemented by infusions of heavily
sialylated molecules.
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The pH of body fluids in healthy individuals spans a very broadrange in different tissue types and organs, ranging from pH
1.5 (stomach contents) to 8.0 (urine). Human cells in tissue
culture can also tolerate a wide range of pH values. In contrast,
blood pH is tightly regulated between 7.35 and 7.45 (1), and
departure out of this range (acidosis or alkalosis) can be very
detrimental. For example, in the recent COVID-19 pandemic,
30% of nonsurvivors had acidosis, compared to 1% among sur-
vivors (2). Acidosis in sepsis is partly due to lactic acid release
from anoxic tissues, which overwhelms the buffering capacity of
circulating blood (3). A “cytokine storm” of proinflammatory
mediators in sepsis triggers a cascade of destructive outcomes
such as multiple organ failure (4–8) as currently seen in severe
cases of COVID-19 infection (9). The mechanisms underlying
lethality associated with low blood pH are not clear but include
low zinc levels and release from apoptotic or necrotic cells of
High mobility group box 1 (HMGB1), a damage-associated
molecular pattern (DAMP) defined as one of the late media-
tors of sepsis, further up-regulating many other proinflammatory
cytokines (10–12). Importantly, a recent study indicates that
HMGB1 levels are strongly associated with mortality in patients
infected with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) (13). Here we show that sialylated plasma gly-
coproteins bind HMGB1 to suppress its ability to promote in-
flammatory responses in a zinc- and pH-dependent manner.
Besides providing an explanation for the very tight regulation of
blood pH, these findings provide an avenue for developing a new
therapeutic strategy for treating sepsis.
Results
Mimicking Lactic Acidosis Ex Vivo in Hirudin-Anticoagulated Whole
Blood. In vivo studies of acidosis and sepsis involve many com-
plex factors and interactions. On the other hand, ex vivo re-
constitution of purified blood components can result in artifacts;
for example, neutrophils get activated when separated away from
erythrocytes and plasma (14). To study the significance of tightly
regulated blood pH ex vivo, we sought to create a whole-blood
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system mimicking lactic acidosis. Conventional anticoagulation
with ethylenediaminetetraacetic acid (EDTA) or citrate abro-
gates divalent cation functions, and heparin has many biological
effects independent of anticoagulation. We have previously
shown that the leech protein hirudin can be used for whole-
blood anticoagulation in vitro (15). When lactic acid was
added to freshly collected hirudin-anticoagulated whole blood,
the pH first rose until a concentration of about 1 mM lactic
acid was reached. Further addition then caused a sharp drop in
blood pH (SI Appendix, Fig. S1). Such an initial rise in blood
pH followed by a subsequent drop is seen in patients with
sepsis (16). To further develop this model, we introduced
HMGB1, a DAMP (17–19) associated with poor prognosis in late
sepsis (20, 21).
Neutrophils in Whole Blood Are Activated by HMGB1 at Low pH due to
Better Binding, and Activation Is Attenuated with an HMGB1-Blocking
Antibody. Interaction of HMGB1 with Toll-like receptors (TLRs)
during sepsis is well-documented (22). The proinflammatory
activity of HMGB1 is due to binding to targets such as TLR-2,
TLR-4, TLR-9, and RAGE that are expressed on leukocytes and
endothelial cells (23, 24). We, therefore, introduced exogenous
HMGB1 into our whole-blood acidosis model and tracked
CD11b expression on neutrophils, as a sensitive marker of acti-
vation triggered by HMGB1. Increased neutrophil activation was
noted when HMGB1 was incubated with whole blood at low pH as
compared to physiological pH (Fig. 1A). This effect was partially
attenuated by adding HMGB1 blocking antibody (Fig. 1B). It is
noteworthy that the pH itself does not have an impact on the ac-
tivation status of the neutrophils, as there was no difference in the
expression of CD11b at pH 7.2 and pH 7.5 (Fig. 1A). Enhanced
activation at low pH coincides with increased HMGB1 binding to
neutrophils and monocytes (compare Fig. 2 A and B). Thus,
physiological blood pH limits interaction of HMGB1 with leuko-
cyte receptors, suggesting natural inhibitor(s) of HMGB1 interac-
tion in blood. Looking for candidate inhibitors, we noted earlier
evidence that HMGB1 can interact with CD24 and CD52, two
heavily sialylated proteins (25, 26) in a trimolecular complex with
Siglec-10, a known sialic acid-binding protein. CD52-Fc bound
specifically to the proinflammatory Box B domain of HMGB1, and
this, in turn, promoted binding of the CD52 N-linked glycan sialic
acid with Siglec-10 (26). Furthermore, sialidase treatment abol-
ished CD52 binding to HMGB1, indicating that HMGB1 might
be a sialic acid-binding lectin. Since normal blood plasma con-
tains ∼2 mM sialic acid attached to glycans on plasma proteins
(27), we hypothesized that the unknown natural inhibitor might
be the sialome (the total sum of all sialic acids presented on
plasma glycoproteins).
Among Divalent Cations, Only Zinc Supported the Robust Binding of
HMGB1 with Sialylated Glycoproteins at Physiological pH. The
binding buffer used in prior HMGB1 studies included millimolar
concentrations of manganese cation (Mn2+), a feature likely
carried over from the unrelated function of nuclear HMGB1
binding to DNA. Looking at earlier studies of the interaction of
HMGB1 with CD24 and CD52, we noticed that all those ex-
periments were performed in a buffer containing millimolar
Mn2+ concentrations (25, 28–30). These concentrations were
very high in comparison with the physiological levels of Mn2+ in
the blood (4 to 15 μg/L). We predicted that there might be other
divalent cation(s) that are better cofactor(s) for HMGB1 and
facilitate its binding with sialic acids. Indeed, upon testing mi-
cromolar concentrations of many divalent cations, we found that
only zinc cation (Zn2+) supported robust binding with sialylated
glycoproteins (Fig. 3A). We tested α1-acid glycoprotein and 3′-
sialyllactose as binding partners for HMGB1 in the presence of
different cations and again found that only Zn2+ facilitated
binding. There was a modest binding of 3′-sialyllactose with
HMGB1 in the presence of Mn2+, but the robust binding was
only seen with Zn2+-containing buffer (Fig. 3B).
Replacing Plasma with Buffer at Physiological pH Allows HMGB1 to Activate
Neutrophils, Suggesting Sequestration by Plasma Sialoglycoproteins.
We next asked which whole-blood components were preventing
neutrophil activation under physiological conditions. Hirudin-
anticoagulated whole blood at physiological pH was spun down
and plasma either replaced with Hepes buffer (pH 7.5) supple-
mented with Zn2+ or with the same plasma that had been re-
moved. After incubating with HMGB1, neutrophils were in a
more activated state when incubated in the buffer as compared
to when plasma was added back (Fig. 4A). Part of this effect was
mediated by the exogenously added HMGB1 (SI Appendix, Fig.
S2). Independent studies have shown that HMGB1 binds to si-
alic acid on glycoproteins (26, 31) and we posited that the
∼2 mM bound sialic acid present on plasma glycoproteins might
lead to sequestration of HMGB1 under physiological condition.
We also tested the effect of pH on the binding of HMGB1 to α1-
acid glycoprotein and found that optimal binding was at physi-
ological pH, with less binding at pH 7.2 with buffer containing
Zn2+ (Fig. 4B).
Sialoglycan Array Studies of HMGB1 Confirm That It Is a Sialic
Acid-Binding Lectin with Optimal Binding at Physiological Blood pH
in the Presence of Zinc Cations. We previously reported a sialo-
glycan microarray platform used to identify, characterize, and
validate the Sia (sialic acid)-binding properties of proteins, lec-
tins, and antibodies (32–34). After identifying Zn2+-dependent
HMGB1 binding to sialoglycoproteins, we next investigated the
ability of HMGB1 to bind with multiple sialoglycans abundantly
found in plasma proteins. We performed sialoglycan array
studies of HMGB1 under four different conditions: 1) at physi-
ological pH with Zn2+, 2) at physiological pH without Zn2+, 3) at
pH 7.2 with Zn2+, and 4) at pH 7.2 without Zn2+. These array
studies further confirmed the binding of HMGB1 with multiple
sialylated glycan sequences that are typically found on plasma
glycoproteins, in pH- and Zn2+-dependent fashion (Fig. 5 A and
B, respectively). Additionally, we checked the binding of HMGB1
to sialic acids in sialoglycan microarray using 0, 15, and 150 μM
Fig. 1. Mimicking sepsis by adding lactic acid to whole blood triggers ac-
tivation of neutrophils by HMGB1, which is partially attenuated by an
HMGB1-blocking antibody. CD11b expression was determined by flow
cytometry after incubating whole blood with/without HMGB1 (1 μg/mL). (A)
Neutrophils are activated when incubated with HMGB1 in whole blood at
pH 7.2 (chromatograms: red, isotype control; blue, whole blood at pH 7.5;
orange, whole blood at pH 7.2; green, whole blood at pH 7.5 with HMGB1;
cyan, whole blood at pH 7.2 with HMGB1). (B) Activation is partially atten-
uated with an HMGB1-blocking antibody (50 μg/mL) (chromatograms: red,
isotype control; blue, whole blood at pH 7.2; green, whole blood at pH 7.2
with HMGB1; orange, whole blood at pH 7.2 with HMGB1 and an HMGB1-
blocking antibody). The result is representative of three independent ex-
periments on the blood of a healthy individual.
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concentrations of Zn2+ and observed a dose-dependent effect
(Fig. 5A). This assay showed the relevance of Zn2+ in this binding
phenomenon at a physiological concentration (∼100 μM). There
was an abundant binding of HMGB1 to sialylated probes in glycan
array at physiological pH compared to lower pH (Fig. 5B). On
resolving the binding of HMGB1 at physiological pH and in the
presence of zinc, the binding on the microarray was exclusively to
sialylated glycans confirming our findings (Fig. 5C). A heat-map
representation of all these findings and HMGB1 binding to
individual glycosides is provided in SI Appendix, Figs. S5 and S6,
respectively.
Heparin, a Previously Known Anionic Glycan Binding Partner of HMGB1,
Does Not Exhibit pH Sensitivity, and Zn2+ Only Partially Facilitates
Binding. HMGB1 is known to bind heparin, a heavily sulfated
glycan carrying many negatively charged groups (35, 36). We
checked the binding of HMGB1 with heparin at different pH
values and found that unlike binding with Sia it was not pH-sensitive
Fig. 2. Mimicking sepsis by adding lactic acid to whole blood triggers binding of HMGB1 to leukocytes. (A) Ability of HMGB1 to bind to different cell types of
the blood (erythrocytes, monocytes, and neutrophils) was determined by using different concentrations (100 ng/mL, 500 ng/mL, and 5 μg/mL) of HMGB1 at
physiological conditions. (B) Different cell types of blood were used for binding with HMGB1 (100 ng/mL) at physiological and lower pH (pH 7.2, adjusted with
lactic acid). The data show one representative flow cytometry histogram result of two separate blood samples assayed.
Fig. 3. Among divalent cations, only zinc supported robust binding of HMGB1 with sialylated glycoproteins.: (A and B) Multiple divalent cations (labeled in
the figure) were used individually in the binding buffer, each at a concentration of 500 μM and binding with human α1-acid glycoprotein and 3′-sialyllactose
was determined at pH 7.5 using ELISA. The experiments were performed in triplicate where data show mean ± SD. The replicates mentioned were technical
replicates and a t test was performed to find the statistical significance. The following P values were observed: ***P < 0.001 and ****P < 0.0001.
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(SI Appendix, Fig. S3A). Moreover, there was appreciable baseline
binding of HMGB1 with heparin that only increased partially with
Zn2+ supplementation (SI Appendix, Fig. S3B). These data indicate
that the binding of heparin and sialic acid are very different. The
B Box of HMGB1 that mediates sialic acid binding (26) has three
arginine residues (26) that might be involved in sialic acid rec-
ognition. We made single mutants of arginine residues at positions
97, 110, and 163. When we checked the sialic acid binding, we
could not find any difference between either of the mutants and
wild-type (WT) HMGB1 (SI Appendix, Fig. S4). We suspect other
positively charged residues and/or multiple arginines mediate sialic
acid binding.
Based on all the evidence we have gathered, we believe the
chances are that heparan sulfate (HS) will not affect how
HMGB1 interacts with sialylated plasma proteins. We have ac-
tually tested the binding of an HS-binding-deficient quintuple
mutant of HMGB1 (35) to sialyated plasma protein and found
that the mutant showed binding comparable to WT HMGB1 (SI
Appendix, Fig. S8). This result suggests that the HS-binding site
and sialic acid (SA)-binding site are not overlapping, and that
HMGB1 could simultaneously bind both glycans. However, under
pathological conditions the soluble HS content in plasma could
rise. The soluble HS might have an impact on how HMGB1 binds
to myeloid cell surfaces because it could compete with heparan
sulfate proteoglycans (HSPG) expressed by myeloid cells for
HMGB1 binding.
Discussion
Here we report one plausible explanation for the tight regulation
of blood pH between 7.35 and 7.45, showing that even a slight
reduction to pH 7.2 abolishes the zinc-dependent sequestration
of HMGB1 potentially by plasma sialoglycoproteins, releasing it
to bind to activating receptors on neutrophils. HMGB1 was
originally discovered in the cell nucleus (37–40), playing a role in
DNA bending, replication, and transcription (41, 42). Much later,
HMGB1 was found to be passively or actively released in condi-
tions like sepsis, leading to inflammation (21, 41, 43), that is, it is a
DAMP (44). HMGB1 retention inside the nucleus is dictated by
conserved lysine residues (45). Inflammatory stimuli trigger acet-
ylation of these lysine residues and trafficking of HMGB1 to the
Fig. 4. Replacing plasma with a buffer at physiological pH allows HMGB1 to activate neutrophils. (A) One milliliter of blood was drawn from a healthy
individual and spun down. The plasma was replaced either with Hepes buffer containing zinc (500 μM of Zn2+) or with the plasma that had been removed.
Under both conditions HMGB1 was added and incubated and CD11b expression as a marker of neutrophil activation was measured (representative image of
assays on two different blood samples). (B) The binding of HMGB1 to α1-acid glycoprotein was checked with a binding buffer using different pH ranging from
7.1 to 7.8. The following P value was observed: *P < 0.05.
Fig. 5. Sialoglycan array studies of HMGB1 confirm that it is a sialic acid-binding lectin with optimal binding at physiological blood pH in the presence of zinc.
(A) The sialoglycan array was performed to test the binding of HMGB1 with multiple sialylated probes. The binding buffer used for the assay either contained
zinc and was pH 7.5; no zinc, pH 7.5; with zinc, pH 7.2; and no zinc at pH 7.2. The concentration of zinc used was 15 μM and 150 μM (representative image of a
single experiment. Wilcoxon matched pairs signed rank test used. ****P < 0.0001). (B) Additional microarray experiments with 500 μM zinc further resolve the
pH-dependent binding difference (representative image of the mean of two experiments. Unpaired t test with Welch’s correction used to compare the two
groups. ****P < 0.0001). (C) The difference in the level of HMGB1 binding to sialosides and nonsialosides at physiological pH in the presence of 500 μM zinc
(representative image of a single experiment where zinc was used at a concentration of 500 μM. Kolmogorov–Smirnov test used. ****P < 0.0001).
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cytosol, and eventually to the extracellular space. The different
domains of HMGB1 are Box A, Box B, and an acidic tail. While
Box A and Box B possess many arginine and lysine residues, the
acidic tail is enriched with glutamic and aspartic acid residues. Box
B is proinflammatory, whereas Box A behaves like an antagonist
and mimics an anti-HMGB1 antibody (26, 46).
While tumor necrosis factor α and interleukin 1β are released
early during sepsis, HMGB1 is a late mediator expressed only
after about 24 h and remains at elevated levels before death occurs
(47). Many preclinical studies show protection against sepsis upon
injection of blocking antibodies of HMGB1 or injection of Box A
protein (48). The proinflammatory activity of HMGB1 is well
studied. However, the antiinflammatory activity of HMGB1 also
has been documented in multiple studies (49–51). Recently, it was
shown that HMGB1 binds soluble CD52 and this complex binds
with Siglec-10 on T cells, leading to SHP-1 (phosphatase) re-
cruitment that dephosphorylates LCK and Zap70, thus activating
an antiinflammatory cascade (26, 52). In addition, haptoglobin
(49), C1q, and TIM3 also show antiinflammatory activity of
HMGB1 (50, 51).
In this study, we found that in whole blood at physiological pH
there is no interaction of HMGB1 with its receptors on leuko-
cytes. Surprisingly, when we lowered the pH using lactic acid (to
mimic lactic acidosis, a characteristic feature of sepsis) the in-
teraction was restored. Furthermore, the high concentration of
sialic acids in plasma glycoproteins was found to be the likely
inhibitor of interactions between HMGB1 and TLRs. We further
characterized the role of HMGB1 as a sialic acid-binding lectin
and found that zinc is a required cofactor. Moreover, we con-
firmed all our findings with lipopolysaccharide-free HMGB1 and
used a glycan array that detected the binding of HMGB1 with
several sialic acid probes (SI Appendix, Table S1) in a pH- and
zinc-dependent manner.
In this study, we used CD11b as an activation marker of
neutrophils. This is a well-established method to study the activa-
tion/inactivation of neutrophils with the treatment (53–55). There is
an increase in CD11b levels upon activation of neutrophils. We
observed an increase in the CD11b upon reduction in pH accom-
panied by the addition of HMGB1. Taken together, our findings
lead us to propose that under physiological conditions (pH 7.35 to
7.45) and normal zinc concentrations there is a potent binding of
HMGB1 with plasma sialoglycoproteins (Fig. 6, Upper). Under
septic conditions, drops in pH and zinc concentration decrease in-
teractions between HMGB1 and plasma sialoglycoproteins, leading
to the liberation of HMGB1 to bind with TLRs, to enhance in-
flammation (Fig. 6, Lower). Therefore, proinflammatory and anti-
inflammatory activities of HMGB1 are the two sides of the same
coin and are dependent on the different physiological conditions.
While the proinflammatory role of HMGB1 is very well studied,
recent studies have reported an antiinflammatory role for HMGB1
(25, 50–52). The exact mechanism that enables HMGB1 to switch
from its proinflammatory to antiinflammatory role, and vice versa, is
not very well described. One factor known to enable its switch from
being proinflammatory to antiinflammatory is its oxidative state.
The disulfide form of HMGB1 is proinflammatory, and the sulfo-
nate form is involved in the resolution of inflammation (56–58). In
the current study, we have identified another mechanism by which
HMGB1 switches from its proinflammatory to antiinflammatory
role in a pH- and zinc-dependent manner. Sepsis is characterized by
a decrease in pH and zinc concentration of the blood. We hy-
pothesize that under physiological conditions HMGB1 binds with
sialoglycoproteins of blood, keeping it in a quiescent state. During
sepsis, the drop in pH and zinc concentration of the blood leads to
disruption of HMGB1’s binding with sialic acid, enabling the free
HMGB1 to bind with TLRs and RAGE present on immune cells
and the endothelium. This activates a cascade of the inflammatory
response, which if untreated might lead to multiple organ failure or
even death.
The physiological concentration of zinc in the blood is
reported to near 100 μM (59, 60). Levels of zinc in plasma and
serum are the most commonly used parameters to determine the
zinc concentration in the blood. The differences in values of zinc
concentration between serum and plasma in the same individual
have been attributed to 1) different procedures for collecting and
separating serum and plasma and 2) the delay in processing
times for serum and plasma. When both these variables were
controlled for, no differences were observed in plasma and se-
rum zinc concentration (60). There appears to be little variation
in zinc concentration in the blood between different individuals.
The values of zinc concentration in the blood from different
studies are comparable (60). This value is of the same order of
magnitude as the zinc concentration that was used in our study.
Also consistent with our hypothesis are the findings that sur-
vival in mouse models of sepsis can be improved by infusion of
soluble CD52 (61), and that the sialic acid-binding feature of
HMGB1 is restricted to the disulfide form of HMGB1 (26),
which is expected to be formed when the cytosolic reduced form
is released into the oxidizing environment of the bloodstream.
We suggest that the potent proinflammatory effects of HMGB1
are normally kept in check via sequestration by plasma sialogly-
coproteins at physiological pH and zinc levels and are triggered
when pH and zinc levels fall in the late stages of sepsis. In this
regard, it is notable that the acute phase response to inflammation
results in high production of hypersialylated molecules such as α1-
acid glycoprotein from the liver and endothelium, which may then
act as a negative feedback loop (62–65). Current clinical trials that
are independently studying zinc supplementation (ClinicalTrials.
gov Identifier: NCT01328509 NCT02130388) or pH normalization
(NCT03530046) may be more successful if these approaches are
combined, and perhaps supplemented by infusions of heavily sialy-
lated molecules like CD52. Additionally, studies evaluating plasma
exchange in subjects with septic shock (example NCT03366220)
may show superior efficacy if supplemented with zinc infusions
and pH correction. Preclinical studies are presently evaluating the
function of a blocking anti-HMGB1 antibody (66). We performed
our assays with HMGB1 purchased from HMG Biotech, also
produced it in Escherichia coli and finally confirmed findings using
HMGB1 expressed in 293 FreeStyle cells. In order to recapitulate
the characteristics of HMGB1 in septic conditions, we used the
disulfide-linked form in all our assays. Future studies should ad-
dress whether other posttranslational modifications such as acet-
ylation, methylation, phosphorylation, or oxidation have any
further effect on HMGB1’s propensity to bind sialic acids.
Many studies have shown that zinc is protective against sepsis
(67–69). One of these studies reports serum zinc concentration
in sepsis patients of around 4 μM, compared to ∼11 μM in
healthy individuals. Additionally, blood zinc levels usually de-
crease during inflammation because it is sequestered to the nu-
cleus where it is required as a cofactor for expression of
proinflammatory genes and proteins (67, 70, 71). Thus, lowering
of zinc level in the blood is detrimental. The mechanism of ac-
tion for the antiinflammatory effect of zinc is also extensively
studied. These include impact on the microbiome, lowering of
nuclear factor κB levels, chemotaxis and phagocytosis by immune
cells, antioxidative stress, and adaptive immune response (67).
In this regard, it is notable that a recent study also shows the
role of zinc, pH, and ionic strength on the oligomerization of
HMGB1 (72). We did not investigate any role of zinc or pH on
the structural changes or oligomerization of HMGB1. It seems
that at particular pH and zinc concentration a positively charged
residue of HMGB1 is exposed for binding with sialic acid. This
residue may not be surface-available at lower pH and low zinc
concentration. In this study, we could not pinpoint the critical
residue that is important for sialic acid binding.
HMGB1 has been reported to bind many ligands, some of which
are highly negatively charged molecules such as heparin/heparan
Siddiqui et al. PNAS | 5 of 8









































sulfate (35). We wanted to determine if the interaction of
HMGB1 with sialic acid, which is also negatively charged, is a
generic electrostatic charge-based interaction. Upon testing with
heparin, we found that while HMGB1 did bind with heparin it did
not show any pH dependency. Moreover, binding was only par-
tially enhanced in the presence of zinc. This shows that a different
set of amino acid(s) might be required for binding to heparin and
sialic acid. Notably, under physiological conditions sialic acid is
present in the blood, but the concentrations of other anionic
glycans (heparan sulfate, hyaluronic acid, etc.) are low.
Our findings, if confirmed in randomized clinical trials, have
broad implications in the management of sepsis and possibly
other types of acidosis. Sepsis is a significant cause of mortality,
with a recent study implicating it as the cause of twice as many
deaths as earlier estimated (73). These findings are of particular
importance in light of the present COVID-19 pandemic/survi-
vorship in these patients. Acute respiratory distress syndrome, a
deadly complication of the SARS-CoV-2 and SARS-CoV-1, has
been linked with HMGB1 production (74–76). Recent articles
suggest a potential link between HMGB1 and the pathogenesis
of COVID-19 (77, 78). A recent study showed that HMGB1
strongly correlates with mortality in COVID-19 patients (13).
Additionally, another recent study showed 100% of COVID-19
nonsurvivors had sepsis and 30% of these had acidosis (2). While
the Surviving Sepsis Campaign does not suggest the use of
convalescent plasma in critically ill patients (79), the Food and
Drug Administration has approved its use as an investigational
new drug. A small study of five critically ill COVID-19 patients
treated with convalescent plasma showed improvements in
sepsis-related Sequential Organ Failure Assessment scores (80).
A ClinicalTrials.gov search for “COVID” and “convalescent
plasma” on 6 April 2020 yielded nine results of trials ranging
from phase 1 to phase 3. While the circulating antibodies are
likely to be beneficial on their own, the HMGB1-sequestering
properties of plasma sialoglycoproteins may also contribute to
suppressing the “cytokine storm.” These effects are likely to be
further enhanced if plasmapheresis is supplemented with ag-
gressive pH correction and zinc supplementation.
To the best of our knowledge, this is one of the first studies
where the whole-blood acidosis method has been used to study
sepsis. We have previously shown that sialome of red blood cells
(RBCs) can inhibit the activation of neutrophils partly due to
interaction with Siglec-9 (14). We believe there are several other
factors that can modulate the activation of neutrophils. The es-
tablishment of assays for the identification of such factors will be
the focus of future studies.
Materials and Methods
Enzyme-Linked Immunosorbent Assay for Binding of HMGB1 with α1-Acid
Glycoprotein or 3′-Sialyllactose. Five hundred nanograms to 1 μg of HMGB1
recombinant protein (HMG Biotech) diluted with the binding buffer (20 mM
Hepes, 150 mM NaCl, and 500 μM ZnCl2) was immobilized by applying on a
96-well flat-bottom plate (9018; Corning Costar) and incubating overnight at
4 °C. The wells were washed thrice with 200 μL of binding buffer per well,
followed by blocking with 150 μL of 5% bovine serum albumin (BSA) (pre-
pared in binding buffer). The plate was then incubated at room temperature
(RT) for 1 h with shaking. The blocking solution was removed by flicking
plate and tapping at a dry paper towel. Then, 1 μg/well of α1-acid glyco-
protein (112150; Calbiochem-Behring) or 3′-sialyllactose-PAA-biotinylated
(01-038; Glycotech), diluted in binding buffer, was applied on every well
except the secondary antibody control wells which were left with only
Fig. 6. Proposed model of sequestration of HMGB1 by sialoglycoproteins to prevent HMGB1 binding to receptors on leukocytes. A schematic showing the
binding of HMGB1 to sialic acid under physiological pH (Upper) and binding to leukocyte receptors at low pH (Lower).
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binding buffer. The plate was incubated 1 to 2 h at RT on the shaker. The
solution was removed and wells were washed thrice with 200 μL binding
buffer per well. The secondary antibody (Streptavidin-HRP [horseradish
peroxidase], ab7403-500; Abcam) was applied at a dilution of 1:20,000 in
binding buffer and the plate was incubated for 1 h at RT with shaking. Then,
O-phenylenediamine (OPD)-based substrate solution for HRP was prepared
by adding 5 mg of OPD and 25 μL of 30% H2O2 to 15 mL of citrate-PO4−
buffer. One hundred forty microliters of OPD substrate solution was added
to each well and incubated in the dark until color development. Upon color
development, the reaction was stopped using 40 μL of 2N H2SO4 and the
absorbance was acquired at 490 nm with a plate reader. For the enzyme-
linked immunosorbent assay (ELISA) with different divalent cations, the
binding buffer was prepared using the particular cation-containing salt in-
stead of ZnCl2. Each incubation and wash was performed using the respec-
tive binding buffer.
Hirudin-Anticoagulated Whole-Blood Assays. Informed consent was obtained
from healthy individuals after a full protocol was approved by the University
of California San Diego Human Research Protection Programs Institutional
Review Board. Venous blood was collected in hirudin-coated tubes (NC1054637;
Thermo Fisher). Hirudin was chosen as the anticoagulant as EDTA and
heparin interferes with normal bioprocesses (chelation by EDTA and binding
to and modulating cell-surface proteins by heparin). The pH of blood, when
measured at the start of various assays, varied between 7.5 and 7.6 and is
referred to as the “physiological” pH.
Flow Cytometry Analysis for HMGB1 Activation of/Binding to Leukocytes. To
test for neutrophil activation, 100 μL of whole blood was incubated with
1 μg/mL of HMGB1 for 30 min at 37 °C. In this study, we used the side and
forward scatter characteristics in flow cytometer to gate for live neutrophils
(SI Appendix, Fig. S7). This is a routine method to identify the granulocytes,
monocytes, and lymphocytes in flow cytometry. Several other published
studies have utilized this method for gating neutrophils (81–83). CD11b
expression was measured by flow cytometry as described earlier (14, 84).
Blocking with an anti-HMGB1 antibody (Clone 3E8, 651402; BioLegend) was
performed with 50 μg/mL antibody as described earlier (66). For plasma add-
back studies, whole blood was spun down at 500 × g for 5 min and replaced
with Hepes buffer supplemented with 500 μM ZnCl2. Binding assays were
performed with 500 μL of whole blood. The required amount of HMGB1 (0,
100, 500, or 5,000 ng/mL) was added to 500 μL of blood and incubated at
37 °C for 60 min with rotation. After centrifuging at 600 × g for 5 min, the
cells were washed with 1 mL of phosphate-buffered saline (PBS) and finally
resuspended in 100 μL of FACS buffer (1% BSA in PBS with Ca2+/Mg2+) with
anti-HMGB1 antibody (10 μg/mL, 651402; BioLegend). The cells were incu-
bated at 4 °C for 30 min on ice and were washed with 1 mL PBS (containing
Ca2+/Mg2+). The cells were subsequently resuspended in 100 μL of FACS
buffer with a secondary anti-mouse-APC antibody (405308; BioLegend). The
cells were incubated at 4 °C for 30 min on ice and washed with PBS as before.
Ten microliters was taken from each sample for RBC analysis and the rest of
the sample was fixed with 4% paraformaldehyde and incubated on ice for
20 min. The sample was then washed with PBS and subsequently treated
with ACK lysis buffer (A10492-01; Gibco) to perform analysis of RBCs. The
sample was washed and resuspended in 500 μL of FACS buffer. In the for-
ward and side scatter profile, monocytes and neutrophils were gated for the
analysis. For gating of monocytes forward and side scatter pattern was used
(SI Appendix, Fig. S7). Histograms were created using FlowJo and visually
inspected for trends in binding and activation. No statistical analysis was run.
Glycan Array Analysis for the Binding of HMGB1 with Sialic Acids. Chemo-
enzymatically synthesized sialyl glycans were quantitated utilizing DMB
(1,2-diamino-4,5-methylenedioxybenzene) high-performance liquid chro-
matography analysis and were dissolved in 300 mM sodium phosphate
buffer (pH 8.4) to a final concentration of 100 μM. ArrayIt SpotBot Extreme
was used for printing the sialoglycans on NHS-functionalized glass slides
(PolyAn 3D-NHS slides, PO-10400401; Automate Scientific). Purified mouse
anti-HMGB1 antibody (651402, lot B219634; BioLegend) and Cy3-conjugated
goat anti-mouse IgG (115-165-008; Jackson ImmunoResearch) were used.
Fresh Hepes buffer (20 mM Hepes and 150 mM NaCl ± 500 μM ZnCl2) was
prepared immediately before starting the microarray experiments.
The method described in ref. 34 was adapted to perform the microarray
experiment. Each glycan was printed in quadruplet. The temperature (20 °C)
and humidity (70%) inside the ArrayIt printing chamber were rigorously
maintained during the printing process. The slides were left for drying for an
additional 8 h. Printed glycan microarray slides were blocked with pre-
warmed 0.05 M ethanolamine solution (in 0.1 M Tris·HCl, pH 9.0), washed
with warm Milli-Q water, dried, and then fitted in a multiwell microarray
hybridization cassette (ArrayIt) to divide it into eight subarrays. Each sub-
array well was treated with 400 μL of ovalbumin (1% wt/vol) dissolved in
freshly prepared Hepes blocking buffer ± 500 μM of Zn2+ (pH adjusted for
individual experiments) for 1 h at ambient temperature in a humid chamber
with gentle shaking. Subsequently, the blocking solution was discarded, and
a solution of HMGB1 (40 μg/mL) in the same Hepes buffer (± Zn2+, defined
pH) was added to the subarray. After incubating for 2 h at room tempera-
ture with gentle shaking, the slides were extensively washed (first with PBS
buffer with 0.1% Tween20 and then with only PBS, pH 7.4) to remove any
nonspecific binding. The subarray was further treated with a 1:500 dilution
(in PBS) of Cy3-conjugated goat anti-mouse IgG (Fc-specific) secondary an-
tibody and then gently shaken for 1 h in the dark, humid chamber followed
by the same washing cycle described earlier. The developed glycan micro-
array slides were then dried and scanned with a Genepix 4000B (Molecular
Devices Corp.) microarray scanner (at 532 nm). Data analysis was performed
using the Genepix Pro-7.3 analysis software (Molecular Devices Corp.).
Purification of HMGB1 from E. coli and HEK293 FreeStyle. Expression and pu-
rification of full-length murine His-HMGB1 in E. coli were performed as
described before (35). Mutagenesis was performed using a QuikChange site-
directed mutagenesis kit (Agilent).
For HMGB1 expression in mammalian cells, the complete open reading
frame of murine HMGB1 was cloned into pcDNA3.1(+)-C-6His vector
(GenScript). Transfection was performed using FectoPRO transfection re-
agent (Polyplus-transfection). Recombinant His-HMGB1 was produced in 293
FreeStyle cells (Thermo Fisher Scientific). Purification of His-HMGB1 from 293
FreeStyle cell lysate was carried out using Ni Sepharose 6 Fast Flow gel (GE
Healthcare). After purification, His-HMGB1 was 99% pure as judged by
silver staining.
Data Availability.All study data are included in the article and/or SI Appendix.
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